NCT06222203 Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 225 participants in total. It began in 2024-10-09 with a primary completion date of 2034-12-31.

Brief Summary

Background: Neurofibromatosis type 1 (NF1) is a genetic disease that can cause many symptoms. About half of people with NF1 will develop benign (noncancerous) tumors along nerves in the skin, brain, and other parts of the body. Sometimes, though, these tumors can become cancerous. Researchers do not yet know how to predict which tumors will become cancerous. Objective: To test a new method for predicting which benign NF1 tumors will become cancerous. Eligibility: People aged 3 years and older with a clinical or genetic diagnosis of NF1. Design: * Participants will be screened with a review of their medical history. All participants will have a baseline visit. They will have bood tests and imaging scans. They will have a physical exam. They will answer questions about their family history. Participants aged 8 years and older will take tests of their thinking skills and their emotional health. * Some participants may be asked to undergo more tests. These may include another type of imaging scan and a biopsy: A small sample of tissue may be removed from the tumor. * Participants will be divided into two groups: those believed to be at low risk and those believed to be at high risk of developing cancer. * Participants in the high-risk group will be asked to return for their next visit in 1 month to 3 years. * Participants in the low-risk group will be asked to return for their next visit in 6 months to 5 years. * Participants may also have follow-up visits by phone throughout the study. They will be in the study for 10 years.

Eligibility Criteria

* INCLUSION CRITERIA: High-Risk and Low-Risk NF1 Cohorts * Age \>= 3 years old * Participants with clinical or genetic diagnosis of NF1. * Participants with a diagnosis of mosaic or segmental NF1 are also eligible. * Individuals may have (High-Risk Cohort) or not have (Low-Risk Cohort) at least one of the following characteristics: * Microdeletion or 844-848 missense variants or other variants associated with increased risk of malignant peripheral nervous sheath tumor (MPNST) * Family history of MPNST / atypical neurofibromatous neoplasm of unknown biologic potential (ANNUBP) / atypical neurofibromas (ANF) * Personal history of MPNST/ANNUBP/ANF or neurofibroma with CDKN2A loss * Prior radiation therapy at any site * Large plexiform neurofibroma (PN) burden (\>= 350 mL) * Presence \>= 1 DNL at baseline * The ability of the individual, parent/guardian or Legally Authorized Representative (LAR) to understand and the willingness to sign a written consent document for participation. EXCLUSION CRITERIA: High-Risk and Low-Risk NF1 Cohorts \- Inability or unwillingness to undergo MRI imaging INCLUSION CRITERIA: Parent Cohort * Parent or guardian of pediatric individuals (8-17 years old) in High-Risk or Low-Risk Cohorts. * The ability of the parent/guardian or LAR to understand and the willingness to sign a written consent document for parent/guardian participation in this study. EXCLUSION CRITERIA: Parent Cohort \- None.

Contact & Investigator

Frequently Asked Questions

Related Trials